Better Living: Open Doors to Health- Patient Navigators Specially trained patient navigators in the Open Doors to Health program help patients understand the importance of colonoscopies and walk them through the p... By: PartnersHealthCare … Continue reading →

Silver but buy buy By: PastorDowell … Continue reading →

[Purtier placenta] obama speech - Stem Cells research pls call Riway Zoey @ +65 83613188 for more info (deer placenta) By: Zoey Purtier … Continue reading →

Purtier Placenta - Live Stem Cell Therapy (English version) By: Zoey Purtier … Continue reading →

8 Apr 2013 10:56 Esmay Carter's parents are raising cash so she can make a trans-Atlantic trip to the States for pioneering stem cell therapy A baby who was born nine weeks prematurely and weighing about the same size as a small bag of sugar has defied medics. Baby Esmay Carter is lucky to be alive after arriving into the world weighing just over 3lb. Mum Sarah Hall was given the devastating news that the youngster was likely to have severe brain damage and could die following complications surrounding her birth. Yet the eight-week-old has shown she is made of strong stuff and is now recovering at home with her family in Throckley, Newcastle. However, she is likely to have a tough future ahead of her as it is not known if she will ever be able to walk, talk or see. Now her parents are raising cash so she can make a trans-Atlantic trip to the States for pioneering stem cell therapy. Sarah, 28, a shop assistant, said: I knew something was wrong when I went into labour early and I was really scared. Doctors warned me that Esmay could be stillborn and I was to prepare myself for … Continue reading →

CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced data from a meta-analysis of VELCADE-based regimens compared to non-VELCADE-based regimens as induction therapy prior to autologous stem cell transplant (ASCT) in patients with previously untreated multiple myeloma (MM). These data were reported in an oral presentation at the 14th International Myeloma Workshop (IMW) held April 3-7, 2013 in Kyoto, Japan. The median progression-free survival (PFS) was significantly higher with VELCADE-based induction therapy compared to non-VELCADE-based: 35.9 months compared to 28.6 percent respectively (p This meta-analysis demonstrated that VELCADE-based induction therapy improved progression-free survival and overall survival in multiple myeloma patients who underwent autologous transplantation, said Karen Ferrante, M.D., Chief Medical Officer, Millennium. With data from more than 1,500 patients, this meta-analysis underscores the extensive body of evidence, both in clinical trials and real-world experience, that exists for VELCADE. Bortezomib-based versus non-bortezomib-based induction prior to ASCT in multiple myeloma: meta-analysis of phase 3 trials (Abstract #O-11) The primary objectives of this analysis were to compare the post-transplant CR+nCR rates and PFS of VELCADE-based induction therapy (administered IV, twice weekly) with non-VELCADE-based induction in previously untreated patients with MM undergoing ASCT. Secondary endpoints … Continue reading →

MagForce AG / MagForce AG Receives BfArM Approval to Start the Post-Marketing Study in Glioblastoma with NanoTherm Therapy . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * Set-up of NanoActivators(TM) initially in five leading centers in Germany * Start of center initiation in the post-marketing study forthcoming Berlin, Germany, April 08, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start the post-marketing clinical study in recurrent glioblastoma. The approval of the ethics committee was previously granted end of December 2012 and the Company will now proceed to install the required NanoActivators(TM) in the treatment centers and preparing for the clinical study initiation. The trial is an open-label, randomized, controlled study to determine the efficacy and safety of NanoTherm() monotherapy alone and in combination with radiotherapy versus radiotherapy alone in up to 280 glioblastoma patients. It will be conducted in about 15 centers in Germany and will be initially started in five leading centers, including the University Hospitals Berlin, Duesseldorf, … Continue reading →

SAN DIEGO and FOUNTAIN VALLEY, Calif., April 8, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th). IGDRASOL is a privately-held company for which STI was granted an irrevocable option right to acquire. The two companies' combined pipeline features an oncology franchise of potential products with Phase 2/3 data for multiple solid tumor indications as well as two synergistic drug discovery and development platforms, namely the G-MAB human antibody library and MABiT, a proprietary technology to generate antibody formulated drug conjugates (AfDC). Cynviloq (or IG-001) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM. Cynviloq has completed Phase 1 or 2 trials in MBC, NSCLC, pancreatic cancer, ovarian cancer and bladder cancer in the US and/or non-US. IGDRASOL is preparing for an "End of Phase 2" meeting with the U.S. Food & Drug Administration (FDA) targeted for the first half of 2013 regarding Cynviloq. As an … Continue reading →